Tyrosine kinase inhibitors alone as a first-line treatment for patients with non-small-cell lung cancer harboring mutant epidermal growth factor receptor
Toshihiko Iuchi(Chiba Cancer Center), Hironori Ashinuma(Chiba Cancer Center), Masato Shingyoji(Chiba Cancer Center), Taiki Setoguchi(Chiba Cancer Center), Meiji Itakura(Chiba Cancer Center), Yuzo Hasegawa(Chiba Cancer Center), S. IKEGAMI(Chiba Cancer Center), Yasushi Yoshida(The University of Osaka)
Cited by 0
Related Papers
Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma
|Lung Cancer|2013|261
Regulation by Chemokines of Circulating Dendritic Cell Precursors, and the Formation of Portal Tract–Associated Lymphoid Tissue, in a Granulomatous Liver Disease
|The Journal of Experimental Medicine|2000|198
Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations
|International Journal of Clinical Oncology|2014|167
Comparison of 21‐gauge and 22‐gauge aspiration needle during endobronchial ultrasound‐guided transbronchial needle aspiration
|Respirology|2010|141
Phosphine‐Catalyzed β,γ‐Umpolung Domino Reaction of Allenic Esters: Facile Synthesis of Tetrahydrobenzofuranones Bearing a Chiral Tetrasubstituted Stereogenic Carbon Center
|Angewandte Chemie International Edition|2015|118